

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of

French et al.

Serial No.: 10/015,967

Filed: December 7, 2001

For:

INTERLEUKIN-8 HOMOLOGOUS

POLYPEPTIDES AND THERAPEUTIC

USES THEREOF

Group Art Unit: 1645

DEC 0 9 20p3

Examiner: Unknown

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

February 28, 2003

Diora Haddad

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[] 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

 after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37. CFR §1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [X] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filling of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filling of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 USC §120.

[delete BLAST section if not needed, at your discretion] BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the _____, i.e.: full length Xyz ligand sequence against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-(____: end

Serial No.: 10/015,967 Filed: December 7, 2001

Page 3

page #)" (nucleotide) and "BLAST Results B-1 - B-(fill in: end page #)" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]
- [] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: February 28, 2003

Elizabeth M. Barnes

Reg. No. 35,059

Telephone No. (650) 225-4563

09157
PATENT TRADEMARK OFFICE

Sheet	1	of	1

								She	et 1	of <u>1</u>	
FORM	FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office			U.S. Dept. of Commerce	Atty D	ocket No.	Ser	Serial No. 10/015, 967			
				Patent and Trademark Office	P144	7R1	10/				
LIST	OE D	ISCLOSURES CITED E	V ADDI ICANT		I Widely William I The work the William Willia	Appli					
							ch et al.				
(L	Jse sev	veral sheets if necessar	y)			Filing		1	Group		
	-		 		FOREION DATENT DOCUMENT		Dec 2001	1			
Examiner		T		1	FOREIGN PATENT DOCUMENTS	<u>s</u>			1	·	
Examiner Initials		Document Number	Date		Country		Class -	Subclass	Transi Yes	lation No	
\	94	WO 00/00610	06.01.00	PCT					1		
	95	. WO 00/14226	16.03.00	PCT							
3	96	WO 00/55375	21.09.00	PCT							
7	97	WO 00/73454 A	07.12.00	PCT						1	
	98	WO 01/16318 A	08.03.01	PCT							
	99	WO99/63088	09.12.99	PCT							
			OTHER DISCL	OSURE	S (Including Author, Title, Date,	Pertinen	t Pages, et	c.)	<u> </u>	<u> </u>	
	100	Ashkenazi AJ et a (Accession no: AA	1., "Human PRO	842 (UI	NQ473) nucleotide sequence	SEQ ID	NO:164*	DATABASE G	ENESEO O	NLINE	
	100	1	· · · · · ·				,				
	101	Ashkenazi AJ, "Hu (Accession no: AA	man PRO842 (UN B65191)	Q473) r	protein sequence SEQ ID NO): 165.*	DATABASE	GENESEO O	VLINE		
	102	Baker et al., "Me AAZ65001) (Apr 5,	mbrane-bound p 2000)	rotein	PRO842 encoding cDNA" DATA	'ABASE G	ENESEO ON	NLINE (acces	ssion no	:	
	103	BAKER ET AL., "ME 2000)	MBRANE-BOUND P	ROTEIN	PRO842" DATABASE GENESEO (ONLINE	(accessio	on no: AAY66	5668)- (A	pr 5,	
	104	(Accession no: AA	.Y87317) (May 1	1, 2000							
	105	ONLINE (Accession	no:AAZ98202)	(May 11							
	106	(Accession no:AAB	34728) (Jan 26	, 2001)							
	107	Valenzuela D et a (Accession no: AA	l., "Human sec C59829) (Jan 2	reted p 6, 2001	protein encoding DNA clone	vq8 1.	" DATABAS	E GENESEO C	NLINE		
								REC			
								RECI	= V 		
									₩ 200	9 —	
							TE(CH CENTE	A 1600	1 /2900	
							·	<u></u>			
									·		
										_	
Evamina	<u>_</u>	I									

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.